Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 15, 2028

Study Completion Date

December 15, 2028

Conditions
Liver TransplantHepatocellular Carcinoma RecurrentSystemic Treatment
Interventions
DRUG

Systemic therapy

"Atezolizumab-Bevacizumab every 3 weeks until progression or side effects in combination with Standardized immunosuppressive treatment:~Tacrolimus (objective 5-7 ng/ml) Mycophenolate Mofetil 1000 mg per day Corticosteroids at least 5 mg per day Everolimus will be continued if already started before the inclusion (objective 5-7 ng/ml). If everolimus has not been started prior to inclusion, do not start it, but adopt the following protocol: corticoids + Tacrolimus + Cellcept."

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER